New hope for Tough-to-Treat lymphoma patients

NCT ID NCT06539195

Ongoing Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called DZD8586 for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The main goal is to see if the drug can shrink tumors and control the disease. Researchers will also closely monitor patients for any side effects and measure how the drug moves through the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, 300020, China
Research Site

Hefei, Anhui, 230031, China
Research Site

Beijing, Beijing Municipality, 100083, China
Research Site

Guangzhou, Guangdong, 510060, China
Research Site

Nanning, Guangxi, 530016, China
Research Site

Zhengzhou, Henan, 450003, China
Research Site

Wuhan, Hubei, 430023, China
Research Site

Changsha, Hunan, 410031, China
Research Site

Jinan, Shandong, 250117, China
Research Site

Linyi, Shandong, 276002, China
Research Site

Xi’an, Shanxi, 710061, China
Research Site

Chengdu, Sichuan, 610041, China
Research Site

Tianjin, Tianjin Municipality, 300181, China
Research Site

Hangzhou, Zhejiang, 310009, China

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA